No abstract

We conclude that CsA is an effective and safe treatment for patients with severe AD refractory to conventional treatment, provided that the recommended guidelines for its administration are strictly observed. However, in contrast to previous reports, we found that 8% (6/73) of patients experienced a rebound phenomenon after discontinuation of treatment.

Disease activity correlated better with QoL when disease activity was less severe and disease extent ('rule of nines') correlated better with QoL than disease severity. An individual's improvement of 10 points in disease activity was accompanied by only a small improvement in QoL. Other factors than disease activity may influence QoL in patients with AD.

Photosensitivity is found in approximately 3% of patients with AD and the majority are female. Photosensitivity in patients with AD consists of two clinical reaction patterns distinguishable by phototesting. Patients were diagnosed with either AD and co-existing polymorphic light eruption or photosensitive AD.

No abstract